Annovis Bio, Inc.
ANVS
$1.24
-$0.07-5.00%
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 98.89% | 24.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.73% | 84.55% | |||
| Operating Income | 19.73% | -84.55% | |||
| Income Before Tax | 15.82% | -79.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 15.82% | -79.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.82% | -79.03% | |||
| EBIT | 19.73% | -84.55% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 37.52% | -64.42% | |||
| Normalized Basic EPS | 37.16% | -63.50% | |||
| EPS Diluted | 36.73% | -64.42% | |||
| Normalized Diluted EPS | 37.16% | -63.50% | |||
| Average Basic Shares Outstanding | 34.73% | 8.87% | |||
| Average Diluted Shares Outstanding | 34.73% | 8.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||